2013-03-08 07:32:03 -

* COPD alliance signed in December 2009 and broadened to fibrosis in December
    2010
  * Strategic change in therapy area at Roche resulted in conclusion of the
    alliance
  * Galapagos regains full rights to all programs
  * Roche pays Galapagos €5.75 M for work completed in 2012

Mechelen,  Belgium; 8 March 2013 - Galapagos NV (Euronext: GLPG) announced today
that  it agreed with Roche to end their alliance in fibrosis.  Roche will make a
payment  of €5.75 million to Galapagos  for work completed in 2012, contributing
to 2012 Group revenues.

With  the ending of the alliance, Galapagos has regained the worldwide rights to
all  fibrosis assays  and the  targets   discovered  in the alliance.  These novel
targets  were identified in  various unique human  primary cell assays mimicking
fibrosis.   Galapagos will have received  a total of €16  million in upfront and
milestone payments, including this latest payment.

"We regret that Roche ended the alliance due to a strategic change, but the good
news  is that all assets  have returned to Galapagos,"  said Onno van de Stolpe,
CEO  of Galapagos.  "Our plan is to  find another partner to continue the search
for compounds against these debilitating diseases."

About Galapagos
Galapagos  (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with  a  large  pipeline  of  four  clinical, six pre-clinical, and 30 discovery
small-molecule   and   antibody   programs  in  cystic  fibrosis,  inflammation,
antibiotics, metabolic disease, and other indications.
GLPG0634  is an orally-available, selective inhibitor  of JAK1 for the treatment
of  rheumatoid arthritis and  potentially other inflammatory  diseases, about to
enter  Phase  2b studies.   AbbVie  and  Galapagos  signed  a  worldwide license
agreement  whereby  AbbVie  will  be  responsible  for  further  development and
commercialization   after   Phase  2b.  Galapagos  has  another  selective  JAK1
inhibitor  in Phase 2 in lupus and psoriasis, GSK2586184 (formerly GLPG0778, in-
licensed  by GlaxoSmithKline  in 2012).  GLPG0187  is a  novel integrin receptor
antagonist currently in a Phase 1b patient study in metastasis.  GLPG0974 is the
first  inhibitor of GPR43 to  be evaluated clinically for  the treatment of IBD;
this program will start a Proof of Concept Phase 2 study in Q2 2013.
The  Galapagos Group, including fee-for-service  companies BioFocus, Argenta and
Fidelta,  has over 800 employees and operates facilities in five countries, with
global headquarters in Mechelen, Belgium.  Further information at: www.glpg.com

Contact

Galapagos NV
Onno van de Stolpe, Chief Executive Officer
Tel: +31 6 2909 8028

Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com

Galapagos forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks,"
"estimates," "may," "will," "could,"
"stands to," and "continues," as well as similar expressions. Such
forward-
looking statements may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial condition, performance
or achievements of Galapagos, or industry results, to be materially different
from any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, the reader is advised not to place any undue reliance on
such forward-looking statements. These forward-looking statements speak only as
of the date of publication of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.

Galapagos and Roche conclude strategic alliance: 
 hugin.info/133350/R/1683707/551103.pdf



This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
    
Source: Galapagos NV via Thomson Reuters ONE
[HUG#1683707]